The statements on this page have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent disease.
The statements on this page have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent disease.
Serving Size: 2 NutriCaps®
Servings Per Container: 30
Other Ingredients: NutriCaps® Pullulan Capsule, NuFlow® Rice Concentrate.
Suitable for vegans: Contains NO soy, peanut, tree nuts, or wheat. Free of gluten, artificial additives, colors and preservatives. Non-GMO and non-irradiated.
Suggested Use: Take 2 to 4 capsules per day in the morning or early afternoon on an empty stomach.
Amount Per Serving |
% Daily Value |
|
Vitamin B6 (from NutriGenesis®) | 2.5 mg | 55 |
Vitamin B9 (from NutriGenesis®) | 100 mcg | 50 |
Vitamin B12 (from NutriGenesis®) | 7.5 mcg | 160 |
Citicoline | 250 mg | † |
Bacopa Monnieri (as full spectrum extract 24% bacosides with 9 bioactives) (aerial parts) | 150 mg | † |
Organic Lion's Mane Mushroom (mycelium and fruit) | 500 mg | † |
Phosphatidylserine (sunflower lecithin) | 100 mg | † |
N-Acetyl L-Tyrosine | 175 mg | † |
L-Theanine | 100 mg | † |
Rhodiola Rosea (3% rosavins, 1% salidrosides) (root) | 50 mg | † |
Maritime Pine Bark Extract (95% proanthocyanidins) | 75 mg | † |
† Daily Value not established. |
Other Ingredients: NutriCaps® Pullulan Capsule, NuFlow® Rice Concentrate.
Suitable for vegans: Contains NO soy, peanut, tree nuts, or wheat. Free of gluten, artificial additives, colors and preservatives. Non-GMO and non-irradiated.
Suggested Use: Take 2 to 4 capsules per day in the morning or early afternoon on an empty stomach.
"The results of the initial three-month study are impressive, to say the least. I was surprised by the degree of statistical significance. We have submitted our findings to peer-reviewed scientific journals for publication. We are soon to begin work on the next phase.”
Dr Andrea Utley BA (Hons), PGCE, PhD. Reader in Motor Control and Development, University of Leeds
MLP® v4.0 has been subjected to rigorous double-blind, placebo-controlled human trials. Conducted by the University of Leeds in the UK.
The first study was conducted independently and published in the Biomedical Journal of Scientific & Technical Research. A peer-reviewed publisher of ground breaking innovation and research.
A second study - funded by Performance Lab® Group (MLP® parent company) focused on memory. It has been peer-reviewed and accepted for publication in Human Psychopharmacology: Clinical and Experimental.
A third study is in preparation stage, which will utilize EEG brain mapping technology.